Definition/General

Introduction:
-Celiac disease is an immune-mediated enteropathy triggered by dietary gluten in genetically susceptible individuals
-Characterized by small intestinal villous atrophy and crypt hyperplasia
-Also known as gluten-sensitive enteropathy or celiac sprue
-Lifelong condition requiring strict gluten-free diet.
Origin:
-Results from abnormal immune response to gluten proteins (gliadin, glutenin)
-T-cell mediated autoimmune reaction
-Tissue transglutaminase (tTG) acts as autoantigen
-HLA-DQ2/DQ8 genetic predisposition required
-Environmental trigger (gluten) in genetically susceptible host.
Classification:
-Classic celiac disease (GI symptoms, villous atrophy)
-Non-classic celiac disease (extraintestinal symptoms)
-Silent celiac disease (asymptomatic, positive serology)
-Potential celiac disease (positive serology, normal histology)
-Refractory celiac disease (Types I and II).
Epidemiology:
-Prevalence approximately 1% of population worldwide
-Higher prevalence in Europeans and their descendants
-Female predominance (2-3:1)
-Bimodal distribution: early childhood (6 months-2 years) and 3rd-4th decades
-Increasing recognition due to improved diagnostics.

Clinical Features

Presentation:
-Classic: Chronic diarrhea, steatorrhea, abdominal distension, weight loss
-Non-classic: Iron deficiency anemia, osteoporosis, dermatitis herpetiformis, neurological symptoms
-Pediatric: Failure to thrive, growth retardation, irritability
-Adult: Often subtle, non-specific symptoms.
Symptoms:
-Gastrointestinal: Chronic diarrhea (85%), abdominal pain (70%), bloating (75%), steatorrhea
-Systemic: Weight loss (65%), fatigue (80%), iron deficiency anemia (40%)
-Extraintestinal: Bone disease, dental enamel defects, infertility, neurologic symptoms.
Risk Factors:
-HLA-DQ2 (90-95% patients) or HLA-DQ8 (5-10%)
-Family history (10% first-degree relatives)
-Associated conditions: Type 1 diabetes, autoimmune thyroid disease, Down syndrome
-Early gluten introduction (<6 months)
-Viral infections (rotavirus, adenovirus).
Screening:
-Serology: tissue transglutaminase IgA (tTG-IgA), endomysial antibodies (EMA), deamidated gliadin peptides (DGP)
-Total IgA levels (rule out IgA deficiency)
-HLA typing (DQ2/DQ8)
-Small bowel biopsy (gold standard)
-High-risk groups screening recommended.

Master Celiac Disease Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Duodenal biopsies typically small and fragmented
-Loss of normal villous architecture on low power
-Flattened mucosa in severe cases
-Scalloped or nodular endoscopic appearance
-Reduced duodenal folds on endoscopy.
Characteristics:
-Mosaic pattern on endoscopy (patchy involvement)
-Fissuring of duodenal folds
-Loss of villous ridges
-Granular mucosa
-Increased friability
-Pale appearance due to malabsorption.
Size Location:
-Duodenum most severely affected (especially distal duodenum)
-Proximal jejunum also involved
-Patchy involvement possible
-Severity gradient: duodenum > jejunum > ileum
-Multiple biopsies recommended (≥4 from duodenum).
Multifocality:
-Diffuse involvement of small intestine
-Proximal predominance (duodenum/jejunum)
-Patchy distribution in some cases
-Skip areas possible
-Severity varies between biopsy sites.

Microscopic Description

Histological Features:
-Villous atrophy (partial to total)
-Crypt hyperplasia (increased crypt depth)
-Increased intraepithelial lymphocytes (>40/100 epithelial cells)
-Chronic inflammation in lamina propria
-Surface epithelial damage
-Loss of brush border.
Cellular Characteristics:
-Increased intraepithelial lymphocytes (IELs) predominantly CD8+ T cells
-Surface epithelial flattening and loss of polarity
-Enlarged crypt nuclei
-Increased mitotic activity in crypts
-Plasma cell infiltration in lamina propria
-Eosinophils may be present.
Architectural Patterns:
-Villous shortening/atrophy
-Crypt elongation
-Increased villous width
-Surface epithelial disarray
-Lamina propria expansion
-Loss of surface-to-crypt ratio
-Architectural distortion.
Grading Criteria:
-Marsh-Oberhuber classification: Marsh 0: Normal
-Marsh 1: >40 IELs/100 epithelial cells
-Marsh 2: Crypt hyperplasia + increased IELs
-Marsh 3a: Mild villous atrophy
-Marsh 3b: Marked villous atrophy
-Marsh 3c: Total villous atrophy.

Immunohistochemistry

Positive Markers:
-CD3 (highlights intraepithelial lymphocytes)
-CD8 (majority of IELs)
-Ki-67 (increased proliferation in crypts)
-CD117 (mast cells increased)
-Chromogranin (enteroendocrine cells).
Negative Markers:
-Not routinely required
-CD20 (few B cells normally)
-CD4 (minority of IELs).
Diagnostic Utility:
-CD3 facilitates counting of intraepithelial lymphocytes
-CD8 staining confirms T-cell nature of IELs
-Ki-67 demonstrates increased crypt proliferation
-IEL count >40/100 epithelial cells supports diagnosis.
Molecular Subtypes:
-No molecular subtypes
-HLA-DQ2.5 (90% patients)
-HLA-DQ8 (5-10% patients)
-TCR gamma/delta T cells in refractory disease
-Cytokine profile changes with treatment.

Molecular/Genetic

Genetic Mutations:
-HLA-DQ2 (DQA1*05:01, DQB1*02:01) in 90-95%
-HLA-DQ8 (DQA1*03:01, DQB1*03:02) in 5-10%
-Non-HLA genes: IL15RA, RGS1, LPP, SH2B3, TAGAP
-Over 40 susceptibility loci identified
-CTLA4 and PTPN22 variants.
Molecular Markers:
-Tissue transglutaminase upregulation
-IL-15 overexpression
-Interferon-γ production
-Matrix metalloproteinases activation
-Tight junction proteins disruption
-Zonulin elevation.
Prognostic Significance:
-Excellent prognosis with gluten-free diet
-Histological improvement within 6-24 months
-Persistent symptoms suggest non-adherence or refractory disease
-Increased lymphoma risk (enteropathy-associated T-cell lymphoma)
-Early diagnosis improves outcomes.
Therapeutic Targets:
-Strict gluten-free diet (lifelong)
-Dietary counseling and monitoring
-Nutritional supplementation (iron, B vitamins, calcium, vitamin D)
-Corticosteroids for refractory disease
-Immunosuppression (refractory celiac disease type II).

Differential Diagnosis

Similar Entities:
-Tropical sprue
-Common variable immunodeficiency
-Crohn disease
-Giardiasis
-Small bowel bacterial overgrowth
-NSAIDs enteropathy
-Autoimmune enteropathy.
Distinguishing Features:
-Celiac disease: HLA-DQ2/8+, tTG antibodies+
-Tropical sprue: Endemic areas, responds to antibiotics
-CVID: Hypogammaglobulinemia, recurrent infections
-Crohn: Transmural, skip lesions, granulomas
-Giardiasis: Parasites identifiable, acute onset.
Diagnostic Challenges:
-Distinguishing Marsh 1-2 lesions from other causes of increased IELs
-Patchy involvement requiring adequate sampling
-Seronegative celiac disease (rare)
-Potential celiac disease management
-Refractory disease vs non-adherence.
Rare Variants:
-Refractory celiac disease type I (polyclonal IELs)
-Refractory celiac disease type II (clonal IELs)
-Collagenous sprue
-Ulcerative jejunitis
-Enteropathy-associated T-cell lymphoma.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen

Duodenal biopsies, [number] pieces

Villous Architecture

Villous architecture: [normal/mild/moderate/severe atrophy]

Intraepithelial Lymphocytes

Intraepithelial lymphocytes: [count]/100 epithelial cells (normal <40)

Marsh Grade

Marsh Grade: [0/1/2/3a/3b/3c]

Inflammation

Chronic inflammation: [mild/moderate/marked] in lamina propria

Diagnosis

Features consistent with celiac disease, Marsh Grade [X]. Recommend gluten-free diet and follow-up.